Supplementary Figures S1-S5 from Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 1. Synergistic antitumor activity of lisaftoclax combined with alrizomadlin in AML CDX mouse models. Supplementary Figure 2. Mean plasma and tumor drug concentrations in a subcutaneous OCI-AML-3 CDX model in mice. Supplementary Figure 3. Upregulation of P53 and BAX and downregulation of MCL-1 and BCL-xL by lisaftoclax combined with alrizomadlin in RS4;11cells expressing BCL-2G101V mutation. Supplementary Figure 4. Characterization of RS4;11 cells expressing BCL-2 resistant mutants. Supplementary Figure 5. Synergistic antiproliferative activity of combined treatment with lisaftoclax and alrizomadlin in parental RS4;11 cells, RS4;11 cells with WT BCL-2, and venetoclax-resistant RS4;11 cells expressing BCL-2 mutants.
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416627581